Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis

Haematologica

Volumn 98, Issue 9, 2013, Pages

  Spolverini, Ambra ^a   Pieri, Lisa ^a   Guglielmelli, Paola ^a   Pancrazzi, Alessandro ^a   Fanelli, Tiziana ^a   Paoli, Chiara ^a   Bosi, Alberto ^a   Nichele, Ilaria ^b   Ruggeri, Marco ^b   Vannucchi, Alessandro M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Epo levels; Mutations; PH domain

Indexed keywords

ADAPTOR PROTEIN; JANUS KINASE 2; LNK PROTEIN; PROTEIN SH2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; BONE MARROW BIOPSY; ERYTHROCYTOSIS; FEMALE; GENE MUTATION; GENE SEQUENCE; GRANULOCYTE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA;

EPO LEVELS; MUTATIONS; PH DOMAIN;

AGED; COHORT STUDIES; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA; PROTEINS;

EID: 84883649589     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.090175     Document Type: Letter

References (10)

1. Bersenev A, Wu C, Balcerek J, Jing J, Kundu M, Blobel GA, et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest. 2010;120(6):2058-69.
2. Velazquez L, Cheng AM, Fleming HE, Furlonger C, Vesely S, Bernstein A, et al. Cytokine Signaling and Hematopoietic Homeostasis Are Disrupted in Lnk-deficient Mice. J Exp Med. 2002;195(12):1599-611.
3. Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD Jr, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010;116(6):988-92.
4. Ha J-S, Jeon D-S. Possible new LNK mutations in myeloproliferative neoplasms. Am J Hematol. 2011;86(10):866-8.
5. Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 2010;24(10):1713-8.
6. Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med. 2010;363(12):1189-90.
7. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007; 110(4):1092-7.
8. McMullin MF, Wu C, Percy MJ, Tong W. A nonsynonymous LNK polymorphism associated with idiopathic erythrocytosis. Am J Hematol. 2011;86(11):962-4.
9. Hurtado C, Erquiaga I, Aranaz P, Miguéliz I, García-Delgado M, Novo FJ, et al. LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation. Leuk Res. 2011;35(11):1537-9.
10. McMullin MF. Idiopathic erythrocytosis: a disappearing entity. Hematology Am Soc Hematol Educ Program. 2009:629-35.